Sugi Predict

Sugi Predict / Compounds / SCHEMBL3403480

SCHEMBL3403480

SCHEMBL3403480

c1ncc2c(ccc3nc[nH]c32)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4A O75164 1/20 0.37
▸ KDM4B O94953 1/20 0.37
▸ KDM5C P41229 1/20 0.37
▸ KDM4C Q9H3R0 1/20 0.37
▸ KDM5B Q9UGL1 1/20 0.37
▸ KDM3A Q9Y4C1 1/20 0.37
▸ PARP1 P09874 8/20 0.36
▸ PDPK1 O15530 1/20 0.36
▸ CA12 O43570 1/20 0.36
▸ ALOX15 P16050 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ CA9 Q16790 1/20 0.36
▸ TNKS2 Q9H2K2 1/20 0.36
▸ CHEK1 O14757 1/20 0.36
▸ PIM1 P11309 1/20 0.36
▸ AKT1 P31749 1/20 0.36
▸ FLT3 P36888 1/20 0.36
▸ PIM3 Q86V86 1/20 0.36
▸ EGFR P00533 4/20 0.35
▸ TDO2 P48775 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31539943 0.74 LMNA (0.44) KDM4AKDM4BKDM5CKDM4CKDM5B
SCHEMBL2047874 0.74 KDM4A (0.46) KDM4AKDM4BKDM5CKDM4CKDM5B
SCHEMBL30617074 0.74 KDM4A (0.46) KDM4AKDM4BKDM5CKDM4CKDM5B
SCHEMBL450386 0.74 EGFR (0.40) EGFRTDO2
SCHEMBL2231456 0.74 LMNA (0.44) KDM4AKDM4BKDM5CKDM4CKDM5B
SCHEMBL563678 0.74 EGFR (0.37) KDM4AKDM4BKDM5CKDM4CKDM5B
SCHEMBL29429298 0.74 EGFR (0.37) KDM4AKDM4BKDM5CKDM4CKDM5B
SCHEMBL1374558 0.73 PRKCI (0.44) PARP1PDPK1CA12ALOX15SMN1; SMN2
SCHEMBL16896218 0.73 EGFR (0.39) EGFRTDO2
SCHEMBL28378859 0.72 EGFR (0.34) EGFRTDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119264138-A Preparation method of benzimidazolopyrimidine derivative 内江市第二人民医院 2025-01-07 — — CN claimed
CN-107602496-B Chiral complementary alkyl heterocyclic compound and application thereof as bactericide 南京农业大学 2020-10-13 — — CN claimed
CN-119264138-A Preparation method of benzimidazolopyrimidine derivative 内江市第二人民医院 2025-01-07 — — CN disclosed
CN-119264138-A Preparation method of benzimidazolopyrimidine derivative 内江市第二人民医院 2025-01-07 — — CN disclosed
CN-119264138-A Preparation method of benzimidazolopyrimidine derivative 内江市第二人民医院 2025-01-07 — — CN disclosed
CN-113444090-B Compound and application thereof 北京鼎材科技有限公司 2024-04-16 — — CN disclosed
US-11325912-B2 Regio-selective synthesis of imidazo[1,2-a]pyrimidines GENENTECH, INC. (US) 2022-05-10 — — US disclosed
CN-114423763-A Regioselective synthesis of imidazo [1,2-a ] pyrimidines 豪夫迈·罗氏有限公司 2022-04-29 — — CN disclosed
US-11160808-B2 Compounds that enhance Atoh1 expression MASSACHUSETTS EYE & EAR INFIRMARY (US) 2021-11-02 — — US disclosed
US-20200369670-A1 REGIO-SELECTIVE SYNTHESIS OF IMIDAZO[1,2-a]PYRIMIDINES GENENTECH, INC. (US) 2020-11-26 — — US disclosed
WO-2020227576-A1 REGIO-SELECTIVE SYNTHESIS OF IMIDAZO[1,2-A]PYRIMIDINES GENENTECH, INC. (US) 2020-11-12 — — WO disclosed
US-20150157607-A1 Compounds that Enhance Atoh1 Expression MASSACHUSETTS EYE & EAR INFIRMARY 2015-06-11 — — US disclosed
US-8859597-B2 Compounds that enhance Atoh1 expression MASSACHUSETTS EYE & EAR INFIRMARY (US) 2014-10-14 — — US disclosed
EP-2732819-A2 Compounds that enhance Atoh-1 expression MASSACHUSETTS EYE & EAR INFIRMARY (US) 2014-05-21 — — EP disclosed
EP-2254572-B1 COMPOUNDS THAT ENHANCE ATOH-1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRM (US) 2013-10-16 — — EP disclosed
US-20120328580-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY 2012-12-27 — — US disclosed
US-8188131-B2 Compounds that enhance Atoh1 expression MASSACHUSETTS EYE & EAR INFIRMARY (US) 2012-05-29 — — US disclosed
EP-2254572-A2 COMPOUNDS THAT ENHANCE ATOH-1 EXPRESSION Massachusetts Eye & Ear Infirmary (US) 2010-12-01 — — EP disclosed
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-09-17 — — US disclosed
WO-2009100438-A2 COMPOUNDS THAT ENHANCE ATOH-1 EXPRESSION MASSACHUSETTS EYE & EAR INFIRMARY (US) 2009-08-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11325912-B2 Regio-selective synthesis of imidazo[1,2-a]pyrimidines CDK2, P2RY1, P2RX1 KDM4A 2405/4885KDM4B 1746/4885KDM5C 2872/4885
US-20200369670-A1 REGIO-SELECTIVE SYNTHESIS OF IMIDAZO[1,2-a]PYRIMIDINES CDK2, P2RY1, P2RX1 KDM4A 2405/4885KDM4B 1746/4885KDM5C 2872/4885
US-20150157607-A1 Compounds that Enhance Atoh1 Expression DACH1, EZH1, CREBBP KDM4A 1040/4885KDM4B 1734/4885KDM5C 1491/4885
US-20090232780-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION DACH1, EZH1, CREBBP KDM4A 1040/4885KDM4B 1734/4885KDM5C 1491/4885
US-20120328580-A1 COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION DACH1, EZH1, CREBBP KDM4A 1040/4885KDM4B 1734/4885KDM5C 1491/4885
US-11160808-B2 Compounds that enhance Atoh1 expression DACH1, EZH1, CREBBP KDM4A 1040/4885KDM4B 1734/4885KDM5C 1491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.